UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Invests $1.47 Million in Harrow, Inc. (NASDAQ:HROW)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC acquired a new stake in shares of Harrow, Inc. (NASDAQ:HROW) in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 32,678 shares of the company’s stock, valued at approximately $1,469,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned about 0.09% of Harrow at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of Harrow by 21.5% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,283 shares of the company’s stock valued at $57,000 after buying an additional 227 shares during the last quarter. The Manufacturers Life Insurance Company lifted its stake in Harrow by 5.0% in the second quarter. The Manufacturers Life Insurance Company now owns 11,865 shares of the company’s stock valued at $248,000 after acquiring an additional 567 shares during the last quarter. Quest Partners LLC acquired a new position in shares of Harrow during the 3rd quarter worth $29,000. nVerses Capital LLC acquired a new position in shares of Harrow during the 2nd quarter worth $33,000. Finally, Allspring Global Investments Holdings LLC raised its holdings in shares of Harrow by 2,730.7% during the 2nd quarter. Allspring Global Investments Holdings LLC now owns 2,123 shares of the company’s stock valued at $44,000 after purchasing an additional 2,048 shares in the last quarter. Hedge funds and other institutional investors own 72.76% of the company’s stock.

Harrow Stock Up 3.2 %

HROW stock opened at $36.64 on Tuesday. The stock has a market capitalization of $1.31 billion, a price-to-earnings ratio of -38.98 and a beta of 0.69. The company has a 50-day moving average of $46.12 and a two-hundred day moving average of $36.18. Harrow, Inc. has a 52-week low of $9.13 and a 52-week high of $59.23. The company has a debt-to-equity ratio of 3.23, a current ratio of 1.55 and a quick ratio of 1.44.

Analyst Ratings Changes

HROW has been the topic of several analyst reports. Lake Street Capital increased their target price on shares of Harrow from $45.00 to $55.00 and gave the stock a “buy” rating in a research report on Friday, October 4th. B. Riley lowered their price objective on Harrow from $73.00 to $69.00 and set a “buy” rating on the stock in a report on Wednesday, December 4th. Finally, Craig Hallum boosted their target price on Harrow from $45.00 to $65.00 and gave the stock a “buy” rating in a report on Friday, October 4th.

Harrow Company Profile

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.